Covered recipient · General Payments record
AMY SUSAN PALLER
Allopathic & Osteopathic Physicians Pediatrics
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$226,261.75
60 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $152,107.50 | 43 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $65,470.00 | 13 |
| Honoraria | $7,600.00 | 1 |
| Grant | $1,000.00 | 1 |
| Food and Beverage | $69.75 | 1 |
| Education | $14.50 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| SANOFI-AVENTIS U.S. LLC | $52,835.50 | 10 |
| GENZYME CORPORATION | $42,156.00 | 9 |
| PFIZER INC. | $26,000.00 | 4 |
| LEO Pharma Inc. | $23,000.00 | 4 |
| Novartis Pharmaceuticals Corporation | $17,139.75 | 7 |
| LEO Pharma AS | $14,525.00 | 5 |
| UCB SA | $8,300.00 | 2 |
| E.R. Squibb & Sons, L.L.C. | $6,363.00 | 1 |
| Eli Lilly and Company | $5,906.25 | 2 |
| AbbVie Inc. | $5,600.00 | 3 |
| Incyte Corporation | $4,900.00 | 2 |
| Regeneron Healthcare Solutions, Inc. | $4,515.00 | 2 |
| Regeneron Pharmaceuticals, Inc. | $4,041.25 | 3 |
| Almirall LLC | $3,200.00 | 1 |
| Amryt Pharma Holdings Ltd | $2,440.00 | 1 |
| BioCryst US Sales Co., LLC | $2,250.00 | 1 |
| Boehringer Ingelheim International GmbH | $1,440.00 | 1 |
| Amgen Inc. | $850.00 | 1 |
| Acrotech Biopharma LLC | $800.00 | 1 |
Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
AMY SUSAN PALLER
NPI 1861452815 · CMS profile ID 311623
Allopathic & Osteopathic Physicians / Pediatrics
CHICAGO, IL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1861452815?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- AMY SUSAN PALLER, NPI 1861452815, CMS profile ID 311623. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861452815?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). AMY SUSAN PALLER, NPI 1861452815, CMS profile ID 311623. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861452815?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- AMY SUSAN PALLER, NPI 1861452815, CMS profile ID 311623, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1861452815?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
60 matching records · $226,261.75 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–60 of 60.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AbbVie Inc. | $2,400.00 | 03/31/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795481599 | CMS |
| GENZYME CORPORATION | $10,362.00 | 03/29/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843503851 | CMS |
| Novartis Pharmaceuticals Corporation | $2,160.00 | 03/24/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813138083 | CMS |
| LEO Pharma AS | $830.00 | 02/24/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842126355 | CMS |
| Novartis Pharmaceuticals Corporation | $2,160.00 | 02/24/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813138087 | CMS |
| PFIZER INC. | $7,600.00 | 02/22/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833390855 | CMS |
| SANOFI-AVENTIS U.S. LLC | $6,123.00 | 01/25/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843503769 | CMS |
| LEO Pharma Inc. | $1,400.00 | 01/22/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842239033 | CMS |
| AbbVie Inc. | $800.00 | 01/06/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795481593 | CMS |
| LEO Pharma AS | $3,320.00 | 01/04/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842126335 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $61,064.95 | 56 |
| PY2025 | Principal investigator | $607,010.69 | 41 |
| PY2024 | Recipient | $59,361.14 | 68 |
| PY2024 | Principal investigator | $1,012,472.05 | 77 |
| PY2023 | Recipient | $51,367.44 | 81 |
| PY2023 | Principal investigator | $818,187.43 | 93 |
| PY2022 | Recipient | $54,204.43 | 75 |
| PY2022 | Principal investigator | $707,256.38 | 68 |
| PY2021 | Recipient | $52,404.61 | 80 |
| PY2021 | Principal investigator | $556,805.78 | 78 |
| PY2020 | Recipient | $25,390.18 | 30 |
| PY2020 | Principal investigator | $690,260.11 | 53 |
| PY2019 | Recipient | $39,056.51 | 44 |
| PY2019 | Principal investigator | $1,353,895.80 | 62 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
97 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Organon Llc | $2,918.71 | 12/22/2025 | Non-covered Recipient Entity Northwestern University-M.S.S | Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects | No dispute reported | 06/30/2026 | 1173042830 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,053.90 | 12/04/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184269437 |
| Principal investigator 1 | Organon Llc | $3,661.68 | 12/01/2025 | Non-covered Recipient Entity Northwestern University-M.S.S | Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects | No dispute reported | 06/30/2026 | 1173042826 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $375.00 | 12/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184121101 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $275.00 | 12/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184121103 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $416.67 | 12/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184121105 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $275.00 | 12/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184121107 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $868.68 | 12/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184121109 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $340.91 | 12/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184121111 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,368.00 | 11/17/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | A Study to Evaluate the Efficacy Safety and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants | No dispute reported | 06/30/2026 | 1175359496 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $386.75 | 11/07/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184257851 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $1,135.00 | 11/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184121095 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $928.64 | 11/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184121097 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $1,135.00 | 11/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184121099 |
| Principal investigator 1 | Organon Llc | $6,614.87 | 10/28/2025 | Non-covered Recipient Entity Northwestern University-M.S.S | Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects | No dispute reported | 06/30/2026 | 1173042820 |
| Recipient | GENZYME CORPORATION | $500.00 | 10/24/2025 | Covered Recipient Physician | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226111805 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,082.20 | 10/23/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184252780 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,495.91 | 10/03/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184244801 |
| Recipient | ABBVIE INC. | $1,800.00 | 10/01/2025 | Covered Recipient Physician | A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Pediatric Subjects 6 to <12 Years Old with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy | No dispute reported | 06/30/2026 | 1202400381 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $711.87 | 10/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184121085 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $923.78 | 10/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184121087 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $389.00 | 10/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184121089 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $3,426.80 | 10/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184121091 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $375.00 | 10/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184121093 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,168.00 | 09/30/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | REPURPOSING DUPILUMAB FOR MANAGEMENT OF PRURITIC GENETIC INFLAMMATORY SKIN DISORDERS: A SINGLE-SITE PILOT STUDY | No dispute reported | 06/30/2026 | 1184244421 |
| Recipient | GENZYME CORPORATION | $500.00 | 09/17/2025 | Covered Recipient Physician | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226111764 |
| Recipient | GENZYME CORPORATION | $500.00 | 09/17/2025 | Covered Recipient Physician | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226111770 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $1,785.00 | 09/02/2025 | Non-covered Recipient Entity PALLER | A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1234516526 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $110.50 | 08/21/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184229795 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $331.50 | 08/07/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184226297 |
| Principal investigator 1 | ABBVIE INC. | $54,470.56 | 08/06/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202502921 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $40,549.84 | 08/05/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | USING DUPILUMAB TO IMPROVE CIRCADIAN FUNCTION SLEEP AND PRURITUS IN CHILDREN WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184223602 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $331.50 | 07/31/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184222950 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $442.00 | 07/17/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184217224 |
| Principal investigator 1 | Eli Lilly and Company | $18,592.00 | 07/15/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | A PHASE 3, MULTICENTER, LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187886452 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $157,046.26 | 07/09/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | REPURPOSING DUPILUMAB FOR MANAGEMENT OF PRURITIC GENETIC INFLAMMATORY SKIN DISORDERS: A SINGLE-SITE PILOT STUDY | No dispute reported | 06/30/2026 | 1184213371 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $723.08 | 07/04/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184212969 |
| Recipient | GENZYME CORPORATION | $500.00 | 06/26/2025 | Covered Recipient Physician | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226111759 |
| Recipient | GENZYME CORPORATION | $250.00 | 06/26/2025 | Covered Recipient Physician | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226111789 |
| Recipient | GENZYME CORPORATION | $250.00 | 06/25/2025 | Covered Recipient Physician | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients greater than or equal to 6 to less than 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226111801 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $1,785.00 | 06/12/2025 | Non-covered Recipient Entity PALLER | A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1234514905 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $165.75 | 06/12/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184206487 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $805.95 | 06/05/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184204319 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $640.68 | 06/01/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB ADMINISTERED CONCOMITANTLY WITH TOPICAL CORTICOSTEROIDS IN PATIENTS, >=6 YEARS TO <12 YEARS OF AGE, WITH SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184121081 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $1,459.29 | 06/01/2025 | Covered Recipient Physician | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184121083 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $861.20 | 05/28/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184198993 |
| Recipient | GENZYME CORPORATION | $1,250.00 | 05/27/2025 | Covered Recipient Physician | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients greater than or equal to 6 to less than 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226111782 |
| Principal investigator 1 | Organon Llc | $10,312.80 | 05/26/2025 | Non-covered Recipient Entity Northwestern University-M.S.S | Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects | No dispute reported | 06/30/2026 | 1173042012 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $221.00 | 05/15/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184194839 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $165.75 | 05/15/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184194841 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $851.25 | 05/01/2025 | Covered Recipient Physician | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184121071 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $333.32 | 05/01/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB ADMINISTERED CONCOMITANTLY WITH TOPICAL CORTICOSTEROIDS IN PATIENTS, >=6 YEARS TO <12 YEARS OF AGE, WITH SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184121073 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $535.71 | 05/01/2025 | Covered Recipient Physician | NEUROPSYCHOLOGIC ASSESSMENTS OF DUPILUMAB-TREATED ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184121075 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $375.00 | 05/01/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB ADMINISTERED CONCOMITANTLY WITH TOPICAL CORTICOSTEROIDS IN PATIENTS, >=6 YEARS TO <12 YEARS OF AGE, WITH SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184121077 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $246.65 | 05/01/2025 | Covered Recipient Physician | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184121079 |
| Principal investigator 1 | Eli Lilly and Company | $875.54 | 04/23/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | A PHASE 3, MULTICENTER, LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187888562 |
| Principal investigator 1 | Eli Lilly and Company | $78,083.00 | 04/15/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187886456 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,303.20 | 04/15/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184183248 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $2,499.00 | 04/01/2025 | Covered Recipient Physician | NEUROPSYCHOLOGIC ASSESSMENTS OF DUPILUMAB-TREATED ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184121065 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $668.22 | 04/01/2025 | Covered Recipient Physician | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184121067 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $741.07 | 04/01/2025 | Covered Recipient Physician | A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <6 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184121069 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,394.08 | 03/19/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184174430 |
| Recipient | Amgen Inc. | $13,654.66 | 03/12/2025 | Covered Recipient Physician | A Phase 3b, Multi Center, Open-label, Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1246637242 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $110.50 | 03/11/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184170772 |
| Recipient | GENZYME CORPORATION | $500.00 | 03/07/2025 | Covered Recipient Physician | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients greater than or equal to 6 to less than 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226111774 |
| Recipient | GENZYME CORPORATION | $250.00 | 03/07/2025 | Covered Recipient Physician | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients greater than or equal to 6 to less than 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226111795 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,160.66 | 03/04/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184156636 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $640.68 | 03/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184121043 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $640.68 | 03/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184121045 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $640.68 | 03/01/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB ADMINISTERED CONCOMITANTLY WITH TOPICAL CORTICOSTEROIDS IN PATIENTS, >=6 YEARS TO <12 YEARS OF AGE, WITH SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184121047 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $670.68 | 03/01/2025 | Covered Recipient Physician | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184121049 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $750.00 | 03/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184121051 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $190.38 | 03/01/2025 | Covered Recipient Physician | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184121053 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $340.91 | 03/01/2025 | Covered Recipient Physician | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184121055 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $450.00 | 03/01/2025 | Covered Recipient Physician | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184121057 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $247.50 | 03/01/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB ADMINISTERED CONCOMITANTLY WITH TOPICAL CORTICOSTEROIDS IN PATIENTS, >=6 YEARS TO <12 YEARS OF AGE, WITH SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184121059 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $1,021.50 | 03/01/2025 | Covered Recipient Physician | A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <6 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184121061 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $928.64 | 03/01/2025 | Covered Recipient Physician | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184121063 |
| Principal investigator 1 | Eli Lilly and Company | $1,569.42 | 02/25/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF LEBRIKIZUMAB COMPARED TO PLACEBO IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187890136 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,050.16 | 02/25/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184155490 |
| Recipient | ABBVIE INC. | $13,895.39 | 02/22/2025 | Covered Recipient Physician | A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202400377 |
| Recipient | ABBVIE INC. | $47.67 | 02/21/2025 | Covered Recipient Physician | A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202400362 |
| Recipient | ABBVIE INC. | $15.41 | 02/21/2025 | Covered Recipient Physician | A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202400365 |
| Recipient | ABBVIE INC. | $245.95 | 02/21/2025 | Covered Recipient Physician | A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202400370 |
| Recipient | ABBVIE INC. | $15.41 | 02/21/2025 | Covered Recipient Physician | A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202400374 |
| Recipient | ABBVIE INC. | $52.02 | 02/20/2025 | Covered Recipient Physician | A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202400353 |
| Recipient | ABBVIE INC. | $245.95 | 02/20/2025 | Covered Recipient Physician | A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202400358 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $165.75 | 02/18/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184154364 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,823.66 | 02/11/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184153042 |
| Recipient | ABBVIE INC. | $29.30 | 02/07/2025 | Covered Recipient Physician | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202400343 |
| Recipient | ABBVIE INC. | $58.00 | 02/07/2025 | Covered Recipient Physician | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202400346 |
| Recipient | ABBVIE INC. | $57.00 | 02/07/2025 | Covered Recipient Physician | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202400350 |
| Principal investigator 1 | Organon Llc | $5,809.00 | 02/03/2025 | Non-covered Recipient Entity Northwestern University-M.S.S | Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects | No dispute reported | 06/30/2026 | 1173041986 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $331.50 | 01/17/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184148217 |
| Principal investigator 1 | UCB SA | $36,562.00 | 01/15/2025 | Non-covered Recipient Entity Northwestern University | MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) | No dispute reported | 06/30/2026 | 1246657065 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $276.25 | 01/07/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184146022 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $157,046.26 | 01/03/2025 | Non-covered Recipient Entity NORTHWESTERN UNIVERSITY | REPURPOSING DUPILUMAB FOR MANAGEMENT OF PRURITIC GENETIC INFLAMMATORY SKIN DISORDERS: A SINGLE-SITE PILOT STUDY | No dispute reported | 06/30/2026 | 1184144782 |